Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): A randomised, controlled, open-label phase 2 trial

The Lancet Oncology

Volumn 16, Issue 2, 2015, Pages 208-220

  Mesía, Ricard ^a   Henke, Michael ^b   Fortin, Andre ^c   Minn, Heikki ^d   Yunes Ancona, Alejandro Cesar ^e   Cmelak, Anthony ^f   Markowitz, Avi B ^g   Hotte, Sebastien J ^h   Singh, Simron ⁱ   Chan, Anthony T C ^j   Merlano, Marco C ^k   Skladowski, Krzysztof ^l   Zhang, Alicia ^m   Oliner, Kelly S ^m   VanderWalde, Ari ^m   Giralt, Jordi ^n,o  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF FREIBURG   (Germany)

^c LAVAL UNIVERSITY   (Canada)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e Unidad de Oncologia y Servicios de Salud del Estado de Puebla   (Mexico)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h JURAVINSKI CANCER CENTRE   (Canada)

ⁱ SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^j CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^k Oncologia Medica ASOS Croce E Carle   (Italy)

^l INSTITUTE OF ONCOLOGY   (Poland)

^m AMGEN INC   (United States)

ⁿ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^o UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; ASPIRATION; ASPIRATION PNEUMONIA; ASTHENIA; BACTEREMIA; BACTERIAL PNEUMONIA; BLEEDING; BRAIN DISEASE; BRONCHITIS; CACHEXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CEREBROVASCULAR ACCIDENT; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONFUSION; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DEHYDRATION; DERMATITIS; DEVICE INFECTION; DIABETIC KETOACIDOSIS; DIARRHEA; DIGESTIVE SYSTEM INFLAMMATION; DISORIENTATION; DIVERTICULITIS; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPHAGIA; DYSPHONIA; DYSPNEA; EMBOLISM; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEMUR FRACTURE; FEVER; FOLLOW UP; GENERAL CONDITION DETERIORATION; GLOSSODYNIA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEARING IMPAIRMENT; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERKALEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHARYNX CARCINOMA; HYPOPHOSPHATEMIA; HYPOTENSION; INSOMNIA; KIDNEY FAILURE; LARYNGITIS; LARYNX CARCINOMA; LEUKOPENIA; LOCAL REGIONAL CONTROL; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MOUTH CARCINOMA; MOUTH INFECTION; MOUTH ULCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NECK PAIN; NEUTROPENIA; NEUTROPHIL COUNT; OBSTRUCTIVE AIRWAY DISEASE; ODYNOPHAGIA; OPEN STUDY; OROPHARYNX CARCINOMA; OROPHARYNX PAIN; OTALGIA; OTOTOXICITY; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PRURITUS; RADIATION INJURY; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SIDE EFFECT; SKIN INJURY; SKIN TOXICITY; STOMATITIS; STRIDOR; SURVIVAL RATE; THRUSH; TINNITUS; VOMITING; XEROSTOMIA; ADOLESCENT; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; HEAD AND NECK NEOPLASMS; INTERNATIONAL COOPERATION; MIDDLE AGED; MORTALITY; NEOPLASMS, SQUAMOUS CELL; PATHOLOGY; PROGNOSIS; RADIATION DOSE FRACTIONATION; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; CISPLATIN; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; INTERNATIONAL AGENCIES; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SQUAMOUS CELL; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84921893298     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)71198-2     Document Type: Article

References (19)

1. Head and neck cancers, version 1.2012, 04/26/12 National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, (accessed Dec 17, 2012). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
2. Kruser TJ, Armstrong EA, Ghia AJ, et al. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008, 72:534-542.
3. Wirth LJ, Allen AM, Posner MR, et al. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol 2010, 21:342-347.
4. Brittain E, Schlesselman JJ Optimal allocation for the comparison of proportions. Biometrics 1982, 38:1003-1039.
5. Gregoire V, Daisne JF, Geets X, Levendag P Selection and delineation of target volumes in head and neck tumors: beyond ICRU definition. Rays 2003, 28:217-224.
6. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol 2013, 14:697-710. for the SPECTRUM investigators.
7. Ang KK, Zhang QE, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). Proc Am Soc Clin Oncol 2011, 29(suppl):5500. (abstr).
8. Rivera F, Garcia-Castano A, Vega N, Vega-Villegas ME, Gutierrez-Sanz L Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther 2009, 9:1421-1428.
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
10. Pignon JP, Bourhis J, Domenge C, Designe L Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000, 355:949-955. for the MACH-NC Collaborative Group.
11. Ang K, Zhang Q, Wheeler RH, et al. A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome. Proc Am Soc Clin Oncol 2010, 28(suppl):15 5507. (abstr).
12. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21:92-98.
13. Rischin D, Peters LJ, O'Sullivan B, et al. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group. J Clin Oncol 2010, 28:2989-2995.
14. Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012, 30(suppl 5):F34-F54.
15. Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 2012, 30:2102-2111.
16. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010, 363:24-35.
17. Robinson M, Sloan P, Shaw R Refining the diagnosis of oropharyngeal squamous cell carcinoma using human papillomavirus testing. Oral Oncol 2010, 46:492-496.
18. Melkane AE, Auperin A, Saulnier P, et al. Human papillomavirus prevalence and prognostic implication in oropharyngeal squamous cell carcinomas. Head Neck 2014, 36:257-265.
19. Giralt J, Trigo J, Nuyts S, et al. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial. Lancet Oncol 2015; Jan 15, http://dx.doi.org/10.1016/S1470-2045(14)71200-8.